Takeda announces approval of livtencity® (maribavir) in japan for post-transplant cytomegalovirus (cmv) infection/disease that is refractory to existing anti-cmv therapies

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that livtencity® (maribavir) has been approved by the japanese ministry of health, labour and welfare (mhlw) for post-transplant cytomegalovirus (cmv) infection/disease that is refractory to existing anti-cmv therapies.4 livtencity is the first and only post-transplant anti-cmv treatment approved in japan that targets and inhibits pul97 kinase and its natural substrates.1 “we are pleased by the approval.
TAK Ratings Summary
TAK Quant Ranking